vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and Vericel Corp (VCEL). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $92.9M, roughly 1.2× Vericel Corp). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs 25.0%, a 8.4% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 9.0%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
BY vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $92.9M |
| Net Profit | $37.6M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 33.4% | 25.0% |
| Revenue YoY | 9.0% | 23.3% |
| Net Profit YoY | 33.0% | 17.3% |
| EPS (diluted) | $0.83 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $92.9M | ||
| Q3 25 | $115.7M | $67.5M | ||
| Q2 25 | $110.5M | $63.2M | ||
| Q1 25 | $103.1M | $52.6M | ||
| Q4 24 | $104.7M | $75.4M | ||
| Q3 24 | $101.8M | $57.9M | ||
| Q2 24 | $99.4M | $52.7M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $23.2M | ||
| Q3 25 | $37.2M | $5.1M | ||
| Q2 25 | $30.1M | $-553.0K | ||
| Q1 25 | $28.2M | $-11.2M | ||
| Q4 24 | $30.3M | $19.8M | ||
| Q3 24 | $30.3M | $-901.0K | ||
| Q2 24 | $29.7M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 24.1% | ||
| Q3 25 | 43.1% | 5.1% | ||
| Q2 25 | 35.2% | -3.2% | ||
| Q1 25 | 36.4% | -24.3% | ||
| Q4 24 | 38.6% | 24.5% | ||
| Q3 24 | 39.3% | -4.3% | ||
| Q2 24 | 40.4% | -11.5% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | 25.0% | ||
| Q3 25 | 32.1% | 7.5% | ||
| Q2 25 | 27.2% | -0.9% | ||
| Q1 25 | 27.4% | -21.4% | ||
| Q4 24 | 34.3% | 26.3% | ||
| Q3 24 | 29.8% | -1.6% | ||
| Q2 24 | 29.9% | -8.9% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.46 | ||
| Q3 25 | $0.82 | $0.10 | ||
| Q2 25 | $0.66 | $-0.01 | ||
| Q1 25 | $0.64 | $-0.23 | ||
| Q4 24 | $0.68 | $0.40 | ||
| Q3 24 | $0.69 | $-0.02 | ||
| Q2 24 | $0.68 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $354.6M |
| Total Assets | $9.9B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $137.5M | ||
| Q3 25 | $259.0M | $135.4M | ||
| Q2 25 | $218.3M | $116.9M | ||
| Q1 25 | $421.3M | $112.9M | ||
| Q4 24 | $563.1M | $116.2M | ||
| Q3 24 | $452.6M | $101.7M | ||
| Q2 24 | $730.5M | $102.5M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $354.6M | ||
| Q3 25 | $1.2B | $321.9M | ||
| Q2 25 | $1.2B | $306.8M | ||
| Q1 25 | $1.1B | $295.5M | ||
| Q4 24 | $1.1B | $292.0M | ||
| Q3 24 | $1.1B | $257.5M | ||
| Q2 24 | $1.0B | $243.0M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $488.0M | ||
| Q3 25 | $9.8B | $453.3M | ||
| Q2 25 | $9.7B | $435.6M | ||
| Q1 25 | $9.6B | $424.6M | ||
| Q4 24 | $9.5B | $432.7M | ||
| Q3 24 | $9.4B | $390.4M | ||
| Q2 24 | $9.6B | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $15.0M | ||
| Q3 25 | $38.3M | $22.1M | ||
| Q2 25 | $16.3M | $8.2M | ||
| Q1 25 | $27.1M | $6.6M | ||
| Q4 24 | $175.2M | $22.2M | ||
| Q3 24 | $19.8M | $10.2M | ||
| Q2 24 | $40.1M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $12.8M | ||
| Q3 25 | $38.0M | $19.5M | ||
| Q2 25 | $15.2M | $81.0K | ||
| Q1 25 | $25.0M | $-7.6M | ||
| Q4 24 | $171.2M | $8.5M | ||
| Q3 24 | $19.1M | $-9.2M | ||
| Q2 24 | $39.4M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 13.8% | ||
| Q3 25 | 32.8% | 28.8% | ||
| Q2 25 | 13.7% | 0.1% | ||
| Q1 25 | 24.3% | -14.5% | ||
| Q4 24 | 163.5% | 11.2% | ||
| Q3 24 | 18.8% | -15.9% | ||
| Q2 24 | 39.7% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 2.4% | ||
| Q3 25 | 0.3% | 3.9% | ||
| Q2 25 | 1.0% | 12.9% | ||
| Q1 25 | 2.0% | 27.0% | ||
| Q4 24 | 3.8% | 18.3% | ||
| Q3 24 | 0.6% | 33.5% | ||
| Q2 24 | 0.7% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 0.65× | ||
| Q3 25 | 1.03× | 4.35× | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | 1.12× | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
